rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

John L. Slebir

SVP General Counsel

Company insider

Files Form 4 as: SVP General Counsel, Dynavax Technologies; SVP, Business Development & GC, Vivus.

Every Form 4 they filed

In numbers

Trades disclosed
73
Buys
0
Sells
5
Bought
$0
Sold
$358K
Companies
2
Companies where not an officer
0
First trade
21 Jan 2011
Last trade
10 Feb 2026
Last filed
10 Feb 2026

Companies traded

Where they are an officer
Dynavax TechnologiesOfficer · Biotechnology · last 10 Feb 20260 buys · 0 sells
VivusOfficer · last 29 Jan 20200 buys · 5 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code U—69,634filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—70,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—16,666filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—28,283filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—50,000filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—50,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—300,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—80,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—88,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—70,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—70,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—16,666filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivativeSEC FORM 4 Code D—28,283filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code A—42,424filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesBiotechnologySEC FORM 4 Code D—42,424filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—300,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—80,000filing
10 Feb 2026filed 10 Feb 2026Dynavax Technologiesoption or derivative · BiotechnologySEC FORM 4 Code D—88,000filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesSEC FORM 4 Code U—69,634filing
10 Feb 2026filed 10 Feb 2026Dynavax TechnologiesSEC FORM 4 Code A—50,000filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed5

Buys in green, sells in red, by the company’s sector.

Related people

Deep Track Biotechnology Master Fund, Ltd.10% owner · 10% owner at Dynavax Technologies, filing Form 4 there in the last year
Francis CanoDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
Scott Dunseth MyersDirector · Director at Dynavax Technologies, filing Form 4 there in the last year
David F. NovackPresident & COO · President & COO at Dynavax Technologies, filing Form 4 there in the last year
Ryan SpencerCEO and Director · CEO and Director at Dynavax Technologies, filing Form 4 there in the last year